Holen Sie sich die Stockscreener-App
11.07
1.69%
-0.19
Handel nachbörslich:
11.10
0.03
+0.27%
Schlusskurs vom Vortag:
$11.26
Offen:
$11.1
24-Stunden-Volumen:
10.85M
Relative Volume:
1.11
Marktkapitalisierung:
$7.56B
Einnahmen:
$6.55B
Nettoeinkommen (Verlust:
$-551.40M
KGV:
-13.70
EPS:
-0.8082
Netto-Cashflow:
$438.90M
1W Leistung:
+6.54%
1M Leistung:
+17.02%
6M Leistung:
-8.96%
1J Leistung:
-16.70%
1-Tages-Spanne:
$10.88
$11.31
1-Wochen-Bereich:
$10.31
$11.47
52-Wochen-Spanne:
$7.265
$15.93
Avantor Inc Stock (AVTR) Company Profile
Firmenname
Avantor Inc
Sektor
Telefon
(610) 386-1700
Adresse
RADNOR CORPORATE CENTER, BUILDING ONE, RADNOR, PA
Compare AVTR vs ISRG, BDX, ALC, MDLN, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVTR
Avantor Inc
|
11.07 | 7.69B | 6.55B | -551.40M | 438.90M | -0.8082 |
ISRG
Intuitive Surgical Inc
|
345.42 | 142.49B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
158.17 | 44.07B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
70.26 | 34.44B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
39.79 | 34.76B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
198.99 | 29.41B | 5.54B | 1.52B | 1.74B | 10.37 |
Avantor Inc Stock (AVTR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-06 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2026-01-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-12-17 | Herabstufung | Jefferies | Hold → Underperform |
| 2025-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-11-04 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2025-10-30 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-10-30 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-08-01 | Herabstufung | Jefferies | Buy → Hold |
| 2025-04-29 | Herabstufung | Goldman | Buy → Neutral |
| 2025-04-28 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-04-28 | Herabstufung | Stifel | Buy → Hold |
| 2025-04-28 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-01-17 | Herabstufung | UBS | Buy → Neutral |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-01-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-12-11 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-09-28 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-07-31 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-07-31 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-06-21 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Hold |
| 2022-10-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-09-14 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-09-09 | Herabstufung | Cleveland Research | Buy → Neutral |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-04-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-30 | Fortgesetzt | Raymond James | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-08-02 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-04 | Eingeleitet | Goldman | Buy |
| 2021-04-29 | Hochstufung | Stifel | Hold → Buy |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-09-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-15 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Hold |
| 2019-08-02 | Eingeleitet | Cleveland Research | Neutral |
| 2019-06-14 | Eingeleitet | Janney | Buy |
| 2019-06-12 | Eingeleitet | Raymond James | Outperform |
| 2019-06-11 | Eingeleitet | Goldman | Buy |
| 2019-06-11 | Eingeleitet | Guggenheim | Buy |
| 2019-06-11 | Eingeleitet | JP Morgan | Overweight |
| 2019-06-11 | Eingeleitet | Jefferies | Buy |
| 2019-06-11 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-06-11 | Eingeleitet | Piper Jaffray | Neutral |
| 2019-06-11 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-06-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-11 | Eingeleitet | SunTrust | Buy |
| 2019-06-11 | Eingeleitet | UBS | Buy |
| 2019-06-11 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Avantor Inc Aktie (AVTR) Neueste Nachrichten
Avantor, Inc. (AVTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Avantor Unit Enters Amendment No. 15 To Credit Agreement On July 14, 2026SEC Filing - TradingView
Avantor Refinances €374.2 Million Euro Term Loans at EURIBO + 2.00% Under Credit Amendment - TradingView
Avantor (NYSE: AVTR) refinances €374,208,296.62 in Euro term loans - Stock Titan
Trading Systems Reacting to (AVTR) Volatility - Stock Traders Daily
Will Avantor (AVTR) beat estimates again in its next earnings report? - MSN
Is Avantor (AVTR) Quietly Redefining Its Healthcare Role With NuSil’s HIV-Prevention Partnership? - simplywall.st
Will Avantor (AVTR) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Avantor Stock Up on NuSil's Expanded HIV Prevention Partnership - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Avantor, Inc. (AVTR) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Avantor Jumps 6.2% Amid Sector-Wide Rally - AlphaStreet
Avantor Inc (AVTR) Stock Up 6.9% and Still Undervalued -- GF Sco - GuruFocus
Avantor expands partnership for HIV prevention ring development By Investing.com - Investing.com Nigeria
Avantor expands partnership for HIV prevention ring development - Investing.com
Avantor expands collaboration to develop a thre... - Pluang
Avantor's® NuSil® Brand Expands Partnership with the Population Council to Develop Long-Acting HIV Prevention Product - PR Newswire
Price to earnings forward of Avantor, Inc. – LSX:A2PJN6 - TradingView
Avantor, Inc. Stock 12‑Month Price Target Raised to $10.31, Implies 1% Downside - TradingView
BofA Securities Adjusts Avantor Price Target to $12 From $10 - Moomoo
Avantor, Inc. (AVTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Avantor (AVTR) Gains Traction Under New Management - Yahoo Finance
Enterprise value to EBITDA forward of Avantor, Inc. – LSX:A2PJN6 - TradingView
Investors in Avantor, Inc. (AVTR): Protect Your Rights – Contact Levi & Korsinsky Before December 29, 2025 - The National Law Review
Avantor stock reflects steady life sciences demand amid global biosciences expansion - ad-hoc-news.de
Bronstein, Gewirtz & Grossman, LLC Is Investigating Avantor, Inc. (AVTR) And Encourages Investors to Connect - ACCESS Newswire
Here's why you should hold Avantor stock in your portfolio for now - MSN
Avantor Inc (AVTR) Stock Up 7.7% and Still Undervalued -- GF Sco - GuruFocus
Avantor stock reflects life science demand amid diversified growth - ad-hoc-news.de
Here's Why You Should Hold Avantor Stock in Your Portfolio for Now - Yahoo Finance UK
Avantor Price Target Raised to $11.00/Share From $9.00 by Citigroup - Moomoo
Avantor Is Maintained at Neutral by Citigroup - Moomoo
Bronstein, Gewirtz & Grossman, LLC Encourages Avantor, Inc. (AVTR) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Avantor Inc focuses on life sciences growth while investors monitor its Nasdaq listing - ad-hoc-news.de
Evercore Maintains Avantor(AVTR.US) With Hold Rating, Raises Target Price to $10.5 - Moomoo
Avantor Is Maintained at In-Line by Evercore ISI Group - Moomoo
Avantor, Inc. (AVTR) Stock Analysis: Navigating a Healthcare Giant with a $7.05 Billion Market Cap - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Avantor, Inc. (AVTR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
AVTR Q1 2026 Earnings: EPS Surges Past Estimates, Stock Gains 3.1%Dividend Cut Risk - dars.gov.et
Is Avantor (AVTR) Stock Cheap After A 71% Five Year Fall? - Yahoo Finance
Does Hedge Fund Accumulation Ahead of Earnings Call Reframe Avantor’s (AVTR) Institutional Confidence Story? - Yahoo Finance
Avantor Inc stock highlights life sciences exposure as investors weigh long term demand - Ad-hoc-news.de
AVTR Shareholders Have Opportunity to Lead Avantor, Inc. Class Ac - The National Law Review
Levi & Korsinsky Notifies Avantor, Inc. (AVTR) InvestorsLead Plaintiff Deadline on December 29, 2025 - The National Law Review
Avantor® to Report Second Quarter 2026 Earnings on Wednesday, Ju - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Avantor, Inc. (AVTR) Investors to Inquire about Securities Investigation - ACCESS Newswire
Avantor® to Report Second Quarter 2026 Earnings on Wednesday, July 29, 2026 - BioSpace
Avantor® to Report Second Quarter 2026 Earnin - Moomoo
Avantor, Inc. (AVTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Join Class Action to Recover Losses from Avantor, Inc. (AVTR) – Contact Levi & Korsinsky Before December 29, 2025 - The National Law Review
Smart Money Is Buying Avantor Inc (AVTR) - The Acquirer's Multiple
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Avantor, Inc. (AVTR) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Finanzdaten der Avantor Inc-Aktie (AVTR)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):